Guía de Práctica Clínica sobre la Atención Integral a las Personas ...

217. Erkinjuntti T, Kurz A, Small GW, Bullock R, Lilienfeld S, DamarajuCV. An open-label extension trial of galantamine in patients with probablevascular dementia and mixed dementia. Clin Ther. 2003; 25(6):1765-82.218. Cahill S. Educational workshops and decision support software increasedetection of dementia in the elderly in primary care settings. EvidBased Ment Health. 2006; 9: 102.219. Erkinjuntti T, Kurz A, Gauthier S, Bullock R, Lilienfeld S, DamarajuCV. Efficacy of galantamine in probable vascular dementia andAlzheimer’s disease combined with cerebrovascular disease: a randomisedtrial. Lancet. 2002; 359(9314): 1283-90.220. Bullock R, Erkinjuntti T, Lilienfeld S. Management of patients withAlzheimer’s disease plus cerebrovascular disease: 12-month treatmentwith galantamine. Dement Geriatr Cogn Disord. 2004; 17(1-2): 29-34.221. Craig D, Birks J. Galantamine for vascular cognitive impairment. CochraneDatabase Syst Rev. 2006; (1): CD004746.222. Orgogozo JM, Rigaud AS, Stoffler A, Mobius HJ, Forette F. Efficacyand safety of memantine in patients with mild to moderate vasculardementia: a randomized, placebo-controlled trial (MMM 300). Stroke.2002; 33(7): 1834-9.223. Wilcock G, Mobius HJ, Stoffler A. A double-blind, placebo-controlledmulticentre study of memantine in mild to moderate vascular dementia(MMM500). Int Clin Psychopharmacol. 2002; 17(6): 297-305.224. Doody RS, Stevens JC, Beck C, Dubinsky RM, Kaye JA, Gwyther L,et al. Practice parameter: management of dementia (an evidence-basedreview). Report of the Quality Standards Subcommittee of theAmerican Academy of Neurology. Neurology. 2001; 56(9): 1154-66.225. López-Arrieta J, Birks J. Nimodipina para la demencia degenerativaprimaria, mixta y vascular. Reproducción de una revisión Cochrane,traducida y publicada en La Biblioteca Cochrane Plus, 2008, Número2.226. Pantoni L, Del ST, Soglian AG, Amigoni S, Spadari G, Binelli D, et al.Efficacy and safety of nimodipine in subcortical vascular dementia: arandomized placebo-controlled trial. Stroke. 2005; 36(3): 619-24.227. Chertkow H. Alzheimer’s & Dementia: The journal of the Alzheimer’sassociation. Alzheimers Dement. 2007; 3(4).228. Olin J, Shneider L, Novit A, Luczak S. Hidergina para la demencia.Cochrane Database Syst Rev. 2001; (2): CD000359.229. Fioravanti M, Yanagi M. Cytidinediphosphocholine (CDP-choline) forcognitive and behavioural disturbances associated with chronic cerebraldisorders in the elderly. Cochrane Database Syst Rev. 2005; (2):CD000269.310 GUÍAS DE PRÁCTICA CLÍNICA EN EL SNS